Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odevixibat in Alagille Syndrome
NCT04674761Phase 3Completed
- Sponsor
- Albireo Pharma
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Alagille syndrome (ALGS) comparing Odevixibat with Placebo (2 arms). Primary endpoint: Change From Baseline in Scratching Score at 24 weeks. Started Mar 2021; status: completed.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NCT04674761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674761.